Highly pathogenic avian influenza A/H5N1 virus remains a potential pandemic threat, and it is essential to continue vaccine development against this subtype. A local mucosal immune response in the upper respiratory tract may stop influenza transmission. It is therefore important to develop effective intranasal pandemic influenza vaccines that induce mucosal immunity at the site of viral entry.
Svindland, S.C., Pedersen, G.K., Pathirana, R.D., Bredholt, G., Nøstbakken, J.K., Jul-Larsen, Å., et al. (2013). A study of Chitosan and c-di-GMP as mucosal adjuvants for intranasal influenza H5N1 vaccine. INFLUENZA AND OTHER RESPIRATORY VIRUSES, 7(6), 1181-1193 [10.1111/irv.12056].
A study of Chitosan and c-di-GMP as mucosal adjuvants for intranasal influenza H5N1 vaccine
Montomoli, Emanuele;
2013-01-01
Abstract
Highly pathogenic avian influenza A/H5N1 virus remains a potential pandemic threat, and it is essential to continue vaccine development against this subtype. A local mucosal immune response in the upper respiratory tract may stop influenza transmission. It is therefore important to develop effective intranasal pandemic influenza vaccines that induce mucosal immunity at the site of viral entry.
| File | Dimensione | Formato | |
|---|---|---|---|
|
038-2012_INFLUENZA-Svindland.pdf
accesso aperto
Licenza:
Creative commons
Dimensione
660.58 kB
Formato
Adobe PDF
|
660.58 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
https://hdl.handle.net/11365/976228
Attenzione
Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo